WCT selected to conduct Ph III NurOwn Trial in ALS

By Melissa Fassbender

- Last updated on GMT

Worldwide Clinical Trials is a contract research organization (CRO) with offices in North and South America, Eastern and Western Europe, Russia, and Asia. (Image: iStock/BernardaSv)
Worldwide Clinical Trials is a contract research organization (CRO) with offices in North and South America, Eastern and Western Europe, Russia, and Asia. (Image: iStock/BernardaSv)
BrainStorm Cell Therapeutics has contracted Worldwide Clinical Trials (WCT) to conduct its planned Phase III study of NurOwn in the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm Cell Therapeutics is developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases.

According to New Jersey-based company, a study kick-off meeting is expected later this month.

The company has an exclusive, worldwide licensing agreement with Ramon, Tel Aviv University’s technology transfer company, through which it holds the rights to develop and commercialize the NurOwn technology.

NurOwn previously demonstrated a clinically meaningful benefit of the technology in a randomized, double-blind, placebo-controlled clinical trial conducted in the US.

Subsequently, Brainstorm will conduct a randomized, double-blind, placebo-controlled multi-dose Phase III trial at multiple sites with support from WCT.

Chaim Lebovits, BrainStorm Cell Therapeutics CEO said selecting a contract research organization (CRO) is “a critical step before initiating patient enrollment​” into the company’s Phase III study of NurOwn.

Related news

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars